🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Long-term Follow up Study of EXG102-031 in Participants With wAMD

Recruitingn/aAges 50 Years - anyAllGuangzhou Jiayin Biotech Ltd
NCT06859515 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Previously received treatment with EXG102-031 in the study (EXG102-031-111); 2. Paticipantes are informed consent and willingness to follow protocol procedures. Exclusion Criteria: 1\. Paticipantes are unwilling or unable to participate in long-term follow-up
💊

What it tests

  • No intervention, only for observational studies
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy